✦ LIBER ✦

A 12-week, double-blind, placebo-controlled, dose-range finding study of CHF5074 in patients with mild cognitive impairment

✍ Scribed by Joel Ross; Sanjiv K. Sharma; Jaron Winston; Enrico Frigerio; Francesco Fiorentini; Mercedes Fernandez; Luciana Giardino; Dottie Norris; Helen Cicirello; Daniela Casula; Bruno Imbimbo

Book ID: 118468492
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 77 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2012.05.549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1.298 Transdermal lisuride in patients w

1.298 Transdermal lisuride in patients with idiopathic restless legs syndrome: Results from a placebo-controlled, double-blind 12-week dose-finding study with a 48-week open-label extension phase

✍ H. Benes 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Lamotrigine High-Dose Tolerability and S

Lamotrigine High-Dose Tolerability and Safety in Patients with Epilepsy: A Double-Blind, Placebo-Controlled, Eleven-Week Study

✍ Fumisuke Matsuo; Patricia Gay; Jack Madsen; Keith G. Tolman; Douglas E. Rollins; 📂 Article 📅 1996 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 544 KB

Dihydroergocristine in the treatment of

Dihydroergocristine in the treatment of elderly patients with cognitive deterioration: A double-blind, placebo-controlled, dose-response study

✍ Attilio Franciosi; Guido Zavattini 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 572 KB

A four-week double-blind, placebo-contro

A four-week double-blind, placebo-controlled, parallel dose-response study of amlodipine in patients with stable exertional angina pectoris

✍ Stanley H. Taylor; P. Lee; N. Jackson; G. Cocco 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 187 KB

A multicenter, double-blind, placebo-con

A multicenter, double-blind, placebo-controlled phase IIb proof-of-concept dose-ranging study of AZD3480 and donepezil over 12 weeks in patients with mild to moderate Alzheimer's disease

✍ Lutz Frölich; Göran Eckerwall; Nilsson Jonas 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

✍ X. A. Alvarez; R. Cacabelos; M. Laredo; V. Couceiro; C. Sampedro; M. Varela; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB